| Trial-Results center | |||
| Clinical trial results database |
 Feedback
 Home
|
Systematic review and meta-analysis
This trial is included in the following systematic reviews and meta-analyses:
Related trials
PACES (Simonneau), 2008 - Sildenafil vs Placebo
EARLY (Galie), 2008 - Bosentan vs Placebo
ARIES (Galie=, 2008 - Ambrisentan vs Placebo
COMBI (Hoeper), 2006 - Inhaled iloprost vs Placebo
Singh, 2006 - Sildenafil vs Placebo
STEP (McLaughlin), 2006 - Inhaled iloprost vs Placebo
STRIDE-2 (Barst), 2006 - Sitaxsentan vs Placebo
BREATH-5 (Galie), 2006 - Bosentan vs Placebo
SERAPH (Wilkins), 2005 - Bosentan vs Sildenafil
SUPER-1 (Galie), 2005 - Sildenafil vs Placebo
STRIDE-1 (Barst), 2004 - Sitaxsentan vs Placebo
BREATH-2 (Humbert), 2004 - Epoprostenol + Bosentan vs Epoprostenol + placebo
Sastry, 2004 - Sildenafil vs Placebo
Barst, 2003 - Beraprost vs Placebo
BREATHE-1 (Rubin), 2002 - Bosentan vs Placebo
Langleben, 2002 - Terbogrel vs Placebo
AIR (Olschewski), 2002 - Iloprost vs Placebo
ALPHABET (Galie), 2002 - Beraprost vs Placebo
Simmoneau, 2002 - Treprostinil vs Placebo
Channick, 2001 - Bosentan vs Placebo
Badesch, 2000 - Epoprostenol vs control
See also:
BREATH-2 (Humbert) study, 2004 |
|
Tweet
Facebook
 pdf :
Epoprostenol + Bosentan
-
All mecanism for pulmonary hypertension
|
|
Treatments
| Studied treatment |
Epoprostenol + Bosentan (62.5 mg b.i.d for 4 weeks then 125 mg b.i.d)
|
| Control treatment |
Epoprostenol + placebo
|
Patients
| Patients | patients with pulmonary arterial hypertension |
Method and design
| Randomized effectives | 22 / 11 (studied vs. control) |
| Blinding | double blind |
| Follow-up duration | 16 weeks |
| Primary endpoint | pulmonary vascular resistance |
Results
n/N
n/N
All cause death
| Relative risks | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Endpoint | Events (%) | Relative Risk | 95% CI | Endpoint definition in the trial |
Ref | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Studied treat. | Control treat. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| All cause death | 3 / 22 (13,6%) | 0 / 11 (4,5%) | 3,00 | [0,16;54,80] | 10044 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| The primary endpoint (if exists) appears in blod characters | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Reference(s) used for data extraction:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Absolute risk reduction | ||||
| Endpoint | Events rate | Absolute risk reduction (ARR) |
||
|---|---|---|---|---|
| Studied treat. | Control treat. | |||
Meta-analysis of all similar trials:
All mecanism in pulmonary hypertension for all patients
Reference(s)
| Trials register # | NA |
-
Humbert M, Barst RJ, Robbins IM, Channick RN, Gali� N, Boonstra A, Rubin LJ, Horn EM, Manes A, Simonneau G.
.
Eur Respir J 2004;24:353-9
- 10.1183/09031936.04.00028404
Pubmed
|
Hubmed
| Fulltext
(c) 2004-2011 TrialResults-center - All Rights Reserved
Tweet this
notify a friend